CTX Platforms

Company Overview

Snapshot

Founded in March 2018 by Omer Porat and Hagay Shmuely, CTX Platforms operates with 1–10 employees. The company is currently in a Pre-Funding stage.

Business overview

CTX Platforms is a biotechnology company focused on developing targeted technology for the imaging and treatment of brain cancers and other non-CNS tumors. The company is advancing a theranostic system that utilizes magnetic nanoparticles and non-invasive magnetic field heating to destroy cancer cells, particularly in brain tumors. This technology, developed under license from cutting-edge academic centers, aims to provide an adjuvant treatment alongside existing immunotherapy, offering new hope for patients with conditions like GBM. CTX Platforms operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the healthcare and life sciences markets, including patients and providers in the United States.

Company Intelligence Q&A

What is CTX Platforms' primary focus?

CTX Platforms focuses on developing targeted technology for the imaging and treatment of brain cancers and other non-CNS tumors, utilizing a theranostic system based on magnetic nanoparticles.

When was CTX Platforms founded?

CTX Platforms was founded in March 2018.

Who are the founders of CTX Platforms?

CTX Platforms was founded by Omer Porat and Hagay Shmuely.

What is the current status of CTX Platforms?

CTX Platforms is currently non-active, having ceased to operate in July 2023.

In which sector does CTX Platforms primarily operate?

CTX Platforms primarily operates in the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drugs Discovery & Development.